Originally launched in 2008, with an expanded label received in 2013, ENTEREG (alvimiopan) is the first and only FDA-approved therapy to accelerate the time to upper and lower gastrointestinal (GI) recovery in patients following [all] surgeries that include partial bowel resection with primary anastomosis (i.e., re-connection of the bowel following removal of the resected segment).
ENTEREG is an oral, peripherally-acting mu-opioid receptor antagonist. ENTEREG is available only for short-term (15 doses) use in hospitalized patients. Only hospitals that have registered in and met all of the requirements for the ENTEREG Access Support and Education (E.A.S.E.®) ENTEREG REMS program may use ENTEREG. For more information on ENTEREG, including its full prescribing information, the Boxed Warning regarding short-term hospital use and the E.A.S.E. Program, visit www.ENTEREG.com.